Group 1 - The core index, the CESHKB, increased by 2.22% to 9684.5 points with a trading volume of 19.513 billion [1] - The CESHKB index has risen by 21.28% over the past month, 67.37% over the past three months, and 111.44% year-to-date [1] - The index is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, and a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB index include: - CanSino Biologics (13.85%) - Innovent Biologics (9.49%) - WuXi Biologics (8.72%) - 3SBio (8.71%) - BeiGene (8.39%) - WuXi AppTec (7.03%) - Kintor Pharmaceutical (5.02%) - Zai Lab (4.33%) - Nuo Therapeutics (3.91%) - Kingstar Biotech (3.8%) [1] - The CESHKB index is fully composed of companies listed on the Hong Kong Stock Exchange, with 100% of its holdings in the healthcare sector [2]

8月14日恒生指数下跌0.37%，报收25519.32点，全天南向资金通过港股通渠道合计净买入10.34亿港 元。 证券时报·数据宝统计，8月14日港股通全天合计成交金额为1475.43亿港元，成交净买入10.34亿港元。 具体来看，沪市港股通成交金额927.12亿港元，成交净买入16.45亿港元；深市港股通成交金额548.31亿 港元，成交净卖出6.11亿港元。 成交活跃股方面，沪市港股通前十大成交活跃股中，腾讯控股成交额为60.03亿港元，成交金额居首； 其次是阿里巴巴-W、中芯国际，成交金额分别为36.89亿港元、36.59亿港元。以净买卖金额统计，中国 人寿净买入额为13.53亿港元，净买入金额居首，该股收盘股价上涨3.60%。净卖出金额最多的是腾讯控 股，净卖出6.78亿港元，收盘股价上涨0.68%。 深市港股通前十大成交活跃股中，成交额居首的是腾讯控股，成交金额41.88亿港元；其次是中芯国 际、阿里巴巴-W，成交金额分别为21.29亿港元、21.23亿港元。以净买卖金额统计，有5只股为净买 入，净买入金额最多的是阿里巴巴-W，净买入3.13亿港元，该股收盘下跌1.54%。净卖出金额最多的是 腾讯 ...

8月14日港股市场，北水成交净买入10.34亿港元，其中港股通(沪)成交净买入16.45亿港元，港股通(深) 成交净卖出6.11亿港元。 北水净买入最多的个股是中国人寿（601628）(02628)、阿里巴巴-W(09988)、理想汽车-W(02015)。北 水净卖出最多的个股是腾讯(00700)。 | 买卖总额 | 股票名称 | 卖出额 | 买入额 | | | | --- | --- | --- | --- | --- | --- | | 净流入 | | | | | | | 60.03亿 | 腾讯控股 | 33.40亿 | 26.63亿 | -6.78 Z | HK 00700 | | 36.89亿 | 阿里巴巴-W | 19.15 亿 | 17.73 Z | +1.42亿 | HK 09988 | | 36.59亿 | 中芯国际 | | | | | | 18.76亿 | 17.83 乙 | -9340.71万 | HK 00981 | | | | 29.34亿 | 晶泰控股 | 14.00 亿 | 15.34 乙 | -1.34 Z | HK 02228 | | 22.47 乙 | 中国人寿 | 4.47 ...

Group 1 - Southbound funds net bought Hong Kong stocks worth 1.034 billion HKD on August 14 [1] - Major net purchases included China Life Insurance (1.353 billion HKD), Alibaba-W (455 million HKD), Li Auto-W (352 million HKD), and others [1] - Xiaomi has seen continuous net buying from southbound funds for six consecutive days, totaling 3.37216 billion HKD [3] Group 2 - Tencent Holdings experienced a net sell-off of 1.197 billion HKD, while Meituan-W saw a net sell of 386 million HKD [2] - Tencent's stock slightly increased by 0.68%, reaching a peak of 600 HKD, with the company indicating sufficient chip supply for AI training [3] - Alibaba's stock declined by 1.54%, following the restructuring of its internal organization, merging Feizhu and Ele.me into its China e-commerce segment [3]

2025年8月14日当天，腾讯控股(00700)、阿里巴巴-W(09988)、中芯国际(00981)位居沪港通（南向）成 交额前3位，成交额分别为60.03 亿元、36.89 亿元、36.59 亿元；腾讯控股(00700)、中芯国际(00981)、 阿里巴巴-W(09988) 位居深港通（南向）成交额前3位，成交额分别为41.88 亿元、21.29 亿元、21.23 亿 元。 | 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 腾讯控股(00700) | 60.03 亿元 | -6.78 亿元 | | 阿里巴巴-W(09988) | 36.89 亿元 | +1.42 亿元 | | 中芯国际(00981) | 36.59 亿元 | -9340.71 万元 | | 晶泰控股(02228) | 29.34 亿元 | -1.34 亿元 | | 中国人寿(02628) | 22.47 亿元 | +13.53 亿元 | | 小米集团-W(01810) | 20.08 亿元 | +1.34 亿元 | | 美团-W(03690) | 16.33 亿元 | -1.41 亿元 | | 国泰君 ...

每经AI快讯，8月14日，恒生指数下跌0.37%。南向资金今日净买入10.34亿港元。 南向资金成交活跃个股榜单中，净买入个股共9只，金额最多的是中国人寿（2628.HK，收盘价：23.62 港元），净买入13.530亿港元；净卖出个股共4只，金额最多的是腾讯控股（0700.HK，收盘价：590.0 港元），净卖出11.970亿港元。 | 南向资金今日成交活跃个股榜单 | | --- | （记者 张明双） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 | 代码 | 简称 | 收盘价 | 张铁帽 | 净买入金额 | | | --- | --- | --- | --- | --- | --- | | | | (港元) | (%) | (亿港元) | | | 2628.HK | 中国人寿 | 23.62 | 3.60 | 13.53 | . | | 9988.HK | 阿里巴巴-W | 121.8 | -1.54 | 4.55 | . | | 2015.HK | 理想汽车-W | 95.6 | -1.60 | 3.52 | . | | 1530.HK | 三生制药 | 31. ...

Summary of Key Points Core Viewpoint - On August 14, southbound funds recorded a transaction volume of 147.543 billion HKD, with a net inflow of approximately 1.034 billion HKD, indicating active trading in the Hong Kong stock market. Group 1: Net Inflows - Significant net purchases were made in the following companies: - China Life (02628.HK) with a net inflow of 1.353 billion HKD, showing a price increase of 3.60% [2] - Alibaba-W (09988.HK) with a net inflow of 1.42 billion HKD from the Shanghai-Hong Kong Stock Connect and 3.13 billion HKD from the Shenzhen-Hong Kong Stock Connect, despite a price drop of 1.54% [3] - Li Auto-W (02015.HK) with a net inflow of 3.52 billion HKD, experiencing a decline of 1.60% [4] - Sangfor Technologies (01530.HK) with a net inflow of 3.04 billion HKD, increasing by 2.83% [5] - CanSino Biologics (09926.HK) with a net inflow of 2.22 billion HKD, rising by 4.19% [6] - SMIC (00981.HK) with a net inflow of 2.55 billion HKD from the Shenzhen-Hong Kong Stock Connect, despite a slight decrease of 0.10% [7] Group 2: Net Outflows - Major net sales were observed in the following companies: - Tencent Holdings (00700.HK) with a net outflow of 677.8123 million HKD from the Shanghai-Hong Kong Stock Connect and 519.1757 million HKD from the Shenzhen-Hong Kong Stock Connect, with a price increase of 0.68% [8] - Meituan-W (03690.HK) with a net outflow of 141.0263 million HKD from the Shanghai-Hong Kong Stock Connect and 245.3153 million HKD from the Shenzhen-Hong Kong Stock Connect, showing a slight increase of 0.08% [9] - Crystal International (02228.HK) with a net outflow of 134.2188 million HKD from the Shanghai-Hong Kong Stock Connect and 120.6194 million HKD from the Shenzhen-Hong Kong Stock Connect, despite a significant rise of 11.61% [9] - WuXi Biologics (02269.HK) with a net outflow of 18.83193 million HKD from the Shenzhen-Hong Kong Stock Connect, with a minor price increase of 0.06% [9]

Summary of Key Points Core Viewpoint - The Hong Kong stock market saw significant net buying from Northbound funds, with a total net inflow of HKD 10.34 billion on August 14, 2023, indicating strong investor interest in certain stocks, particularly in the insurance and technology sectors [1][2]. Group 1: Northbound Fund Activity - Northbound funds recorded a net buying of HKD 10.34 billion, with HKD 16.45 billion from the Shanghai Stock Connect and a net selling of HKD 6.11 billion from the Shenzhen Stock Connect [1]. - The most net bought stocks included China Life (02628), Alibaba-W (09988), and Li Auto-W (02015), while Tencent (00700) was the most net sold stock [1][2]. Group 2: Individual Stock Performance - China Life (02628) received a net inflow of HKD 13.53 billion, driven by recent industry developments and a favorable outlook for the insurance sector [4]. - Alibaba-W (09988) saw a net buying of HKD 4.55 billion, supported by strong order volumes and strategic moves to enhance its e-commerce platform [5]. - Li Auto-W (02015) had a net inflow of HKD 3.52 billion, following organizational changes aimed at improving sales and service efficiency [5]. - Tencent (00700) experienced a net selling of HKD 11.96 billion, despite reporting a 15% year-on-year revenue growth to HKD 184.5 billion in Q2 2023 [7][8]. Group 3: Sector Insights - The semiconductor sector showed strong interest, with net buying in stocks like SMIC (00981) and Hua Hong Semiconductor (01347), reflecting confidence in domestic supply chains and AI-related developments [7]. - The pharmaceutical sector also attracted attention, with companies like 3SBio (01530) and CanSino Biologics (09926) receiving notable net inflows, driven by strategic partnerships and upcoming clinical trial results [6].

Group 1 - The investment bank maintains a cautiously optimistic view on the Chinese pharmaceutical industry, noting a 137% average increase in Hong Kong biotech stocks since early 2025, driven by cash returns from innovative drug licensing deals [1] - Recent pullbacks in the industry are attributed to disappointing sales figures from major biotech companies and concerns over potential phased drug tariffs proposed by Trump, which could reach 150% within a year and ultimately 250% [1] - The bank's preferred focus is on innovative sectors with strong performance in the first half of 2025, highlighting BeiGene (06160) with a target price of HKD 230 and a rating of "outperform" due to its strong half-year results and improved gross margin guidance [1] Group 2 - The bank expects CanSino Biologics (09926) to report adjusted earnings of RMB 23 million in the first half of 2025, benefiting from revenue growth from its drugs AK104 and AK112, with a rating of "outperform" [1] - The target price for Innovent Biologics (01801) has been raised by 10% from HKD 100 to HKD 110, with a rating of "outperform," reflecting confidence in the company's projected 37% year-on-year growth in product revenue [1] - The bank continues to focus on licensing deals for innovative drugs in China, anticipating more subsidies for high-priced innovative drugs, which may drive sales growth for companies like Kintor Pharmaceutical (02171), Fosun Pharma (600196) (02196), WuXi AppTec (02126), and Kerenor Biotech (06990) [2]

Core Viewpoint - The investment bank maintains a cautiously optimistic outlook on the Chinese pharmaceutical industry, noting a significant average increase of 137% in Hong Kong biotech stocks since early 2025, driven by cash returns from innovative drug licensing deals and unaffected by upcoming U.S. tariffs [1] Group 1: Market Performance - The biotech sector has recently experienced some pullback due to disappointing sales figures from major companies in the first half of 2025, including Hutchison China MediTech [1] - Concerns have arisen regarding Trump's phased implementation of drug tariffs, which could escalate to 150% within a year and ultimately reach 250% [1] Group 2: Company Recommendations - The bank's top pick is BeiGene (06160), with a target price set at HKD 230 and a rating of "Outperform," citing strong performance in the first half of 2025 and an improved gross margin guidance despite U.S. tariff impacts [1] - CanSino Biologics (09926) is expected to report adjusted earnings of RMB 23 million for the first half of 2025, benefiting from revenue growth from its drugs AK104 and AK112, also rated "Outperform" [1] - The target price for Innovent Biologics (01801) has been raised by 10% from HKD 100 to HKD 110, with a rating of "Outperform," reflecting confidence in the company's projected 37% year-on-year revenue growth [1] Group 3: Focus on Innovative Drugs - The bank continues to pay attention to licensing deals for Chinese innovative drugs, with expectations of increased subsidies for high-priced innovative drugs, which may drive sales growth for companies such as Kintor Pharmaceutical (02171), Fosun Pharma (02196), WuXi AppTec (02126), and Kelun-Biotech (06990) [2]